– CANADA, Mississauga – Trillium Therapeutics Inc. (NASDAQ: TRIL | TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that Paul Walker has been appointed to its Board of Directors, and Dr. Ali Behbahani has been appointed as a Board Observer, effective February 6, 2020.
“We are delighted to welcome Mr. Walker to the Board of Directors and Dr. Behbahani as a Board Observer, and look forward to their guidance as we work to bring to patients our CD47 programs,” said Dr. Robert Kirkman, Executive Chair.
“We are excited about Trillium’s recent progress and look forward to working with the leadership team as they expand their clinical development program,” said Paul Walker.
The Company also announced that Dr. Robert Uger, Trillium’s Chief Scientific Officer has resigned from the Board of Directors effective February 6, 2020.
Mr. Walker and Dr. Behbahani are general partners with New Enterprise Associates, a global venture capital firm with more than $20 billion of cumulative committed capital invested in healthcare and technology companies. Prior to joining NEA, Paul worked at MPM Capital as a General Partner with the MPM BioEquities Fund, where he specialized in public, PIPE and mezzanine-stage life sciences investing. Previously, he was a portfolio manager at Franklin Templeton Investments. Paul received a BS in Biochemistry and Cell Biology from the University of California at San Diego, and holds the Chartered Financial Analyst designation.
Dr. Behbahani’s previous positions include a consultant in business development at The Medicines Company, a Venture Associate at Morgan Stanley Venture Partners and as a Healthcare Investment Banking Analyst at Lehman Brothers. He concurrently earned his MD degree from The University of Pennsylvania School of Medicine and his MBA degree from The University of Pennsylvania Wharton School.
About Trillium Therapeutics
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The Company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “do not eat” signal that cancer cells frequently use to evade the immune system.
The Company’s pipeline also includes a preclinical STING agonist program. As previously announced, the program is earmarked for out-licensing.
For more information: https://trilliumtherapeutics.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
